Opportunity Information: Apply for PA 09 114
Apply for PA 09 114
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Manufacturing Processes of Medical, Dental, and Biological Technologies (STTR R41/R42)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121 Oral Diseases and Disorders Research 93.233 National Center on Sleep Disorders Research 93.279 Drug Abuse and Addiction Research Programs 93.286 Discovery and Applied Research for Technological Innovations to Improve Human Health 93.389 National Center for Research Resources 93.393 Cancer Cause and Prevention Research 93.394 Cancer Detection and Diagnosis Research 93.395 Cancer Treatment Research 93.396 Cancer Biology Research 93.399 Cancer Control 93.837 Cardiovascular Diseases Research 93.838 Lung Diseases Research 93.839 Blood Diseases and Resources Research 93.846 Arthritis, Musculoskeletal and Skin Diseases Research 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders 93.855 Allergy, Immunology and Transplantation Research 93.856 Microbiology and Infectious Diseases Research 93.859 Biomedical Research and Research Training 93.866 Aging Research 93.867 Vision Research.
- This funding opportunity was created on Feb 26, 2009 and posted on Feb 26, 2009.
- Applicants must submit their applications by Jan 7, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Manufacturing Processes of Medical, Dental, and Biological Technologies (STTR R41/R42) opportunity (Funding Opportunity Number PA-09-114) is a National Institutes of Health (NIH) funding announcement designed to push more small business-led innovation into the manufacturing side of biomedical technology. It was created in response to Executive Order 13329, signed on February 26, 2004, which directed federal agencies that run SBIR and STTR programs to give high priority to research and development tied to manufacturing, as long as doing so fits the agency mission and legal requirements. In practical terms, NIH is using this announcement to signal that it wants not only new medical, dental, and biological technologies, but also better ways to reliably make them, scale them, and produce them with quality and safety built in.
This program uses the Small Business Technology Transfer (STTR) mechanisms R41 and R42, meaning it supports projects that are carried out by an eligible US small business in formal collaboration with a nonprofit research institution (the STTR model). The announcement allows submissions for Phase I, Phase II, and Fast Track. Phase I generally supports early feasibility and proof-of-concept work, Phase II supports more advanced development and validation as the project moves toward commercialization, and Fast Track is intended to speed the transition by combining Phase I and Phase II into a single streamlined application and review path when a project is ready for that pace. NIH also notes that this STTR announcement runs in parallel with a companion solicitation of the same scientific scope for SBIR applicants (PA-09-113), which uses the SBIR grant mechanisms (R43/R44) instead of STTR.
Scientifically, the focus is on biomedical research that directly advances processing and manufacturing. The announcement highlights areas such as advanced processing approaches, improved manufacturing processes, manufacturing equipment and systems, and even manufacturing workforce skills and worker protection, as long as the work is tied to medical, dental, or biological technologies. The underlying idea is that innovations in manufacturing can be just as critical to public health as the invention itself: better manufacturing can reduce variability, increase throughput, lower costs, improve quality control, strengthen supply chains, and make it easier to meet regulatory expectations for safety and performance.
From a funding and awards standpoint, NIH emphasizes that awards depend on two things: the availability of funds and the receipt of enough high-quality, competitive applications. There is no promised set-aside amount or guaranteed award count listed in the text you provided; instead, NIH states that both the number of awards and total dollars will vary based on the merit, duration, and cost of the applications received. The opportunity is categorized as a discretionary grant and sits within NIHs broader health and education-related research funding landscape.
Eligibility is limited to small businesses, consistent with STTR requirements, and the program spans a wide range of NIH mission areas. The CFDA numbers included in the listing show that this manufacturing-focused solicitation can align with many different disease and research domains across NIH, including but not limited to oral health, sleep disorders, drug abuse, cancer (multiple sub-areas), cardiovascular and lung diseases, blood disorders, arthritis and musculoskeletal conditions, neuroscience and neurological disorders, allergy and immunology, infectious diseases, general biomedical research, aging, and vision research. That breadth is important because it implies the manufacturing innovation can be applied to many types of biomedical products and platforms rather than being limited to a single clinical field.
Administratively, the opportunity was posted and created on February 26, 2009, with an original and current closing date of January 7, 2012, and it was archived on February 7, 2012. For applicants or readers needing the full archived announcement, NIH provided an additional information link through the NIH Grants Guide and contact points through the NIH Office of Extramural Research (OER) webmaster for access or technical linking issues.
Frequently Asked Questions (FAQs)
What is the name of this grant opportunity?
The opportunity is titled "The Manufacturing Processes of Medical, Dental, and Biological Technologies (STTR R41/R42)."
What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number is PA-09-114.
Which federal agency is offering this opportunity?
This is a National Institutes of Health (NIH) funding announcement.
What is the main goal of this funding announcement?
The goal is to increase small business-led innovation focused on the processing and manufacturing side of biomedical technology, not just inventing new technologies but improving how medical, dental, and biological technologies are reliably made, scaled, and produced with quality and safety built in.
Why did NIH create this manufacturing-focused program?
The announcement was created in response to Executive Order 13329 (signed February 26, 2004), which directed federal agencies running SBIR and STTR programs to give high priority to manufacturing-related research and development when it fits the agency mission and legal requirements.
What funding mechanism does this program use?
This program uses the Small Business Technology Transfer (STTR) mechanisms R41 and R42.
What does the STTR model require for project structure?
Projects must be carried out by an eligible US small business in formal collaboration with a nonprofit research institution.
What application options are available under this announcement?
The announcement allows submissions for Phase I, Phase II, and Fast Track.
What is Phase I intended to support?
Phase I generally supports early feasibility and proof-of-concept work.
What is Phase II intended to support?
Phase II supports more advanced development and validation as the project moves toward commercialization.
What is the Fast Track option?
Fast Track is intended to speed the transition from Phase I to Phase II by combining them into a single streamlined application and review path when a project is ready for that pace.
Is there a related NIH solicitation for SBIR applicants?
Yes. NIH notes this STTR announcement runs in parallel with a companion solicitation of the same scientific scope for SBIR applicants (PA-09-113), which uses SBIR grant mechanisms (R43/R44) instead of STTR.
What kinds of projects are a fit scientifically?
The focus is on biomedical research that directly advances processing and manufacturing tied to medical, dental, or biological technologies.
What topic areas are specifically highlighted?
Highlighted areas include advanced processing approaches, improved manufacturing processes, manufacturing equipment and systems, and manufacturing workforce skills and worker protection, as long as the work is connected to medical, dental, or biological technologies.
Why is manufacturing innovation treated as important as invention in this program?
The announcement frames manufacturing as critical to public health because better manufacturing can reduce variability, increase throughput, lower costs, improve quality control, strengthen supply chains, and make it easier to meet regulatory expectations for safety and performance.
Is funding guaranteed if an application is submitted?
No. NIH emphasizes that awards depend on the availability of funds and the receipt of enough high-quality, competitive applications.
Does the announcement specify a set-aside funding amount or a guaranteed number of awards?
No. The information provided states there is no promised set-aside amount or guaranteed award count; the number of awards and total dollars will vary based on the merit, duration, and cost of the applications received.
What type of award is this categorized as?
It is categorized as a discretionary grant.
Who is eligible to apply?
Eligibility is limited to small businesses, consistent with STTR requirements, and projects must include formal collaboration with a nonprofit research institution.
Does this opportunity apply to only one disease area or NIH institute?
No. The program spans a wide range of NIH mission areas, implying the manufacturing innovation can apply to many biomedical products and platforms rather than a single clinical field.
What NIH mission areas are indicated by the CFDA numbers mentioned?
The CFDA numbers indicate alignment across many domains, including (but not limited to) oral health, sleep disorders, drug abuse, cancer (multiple sub-areas), cardiovascular and lung diseases, blood disorders, arthritis and musculoskeletal conditions, neuroscience and neurological disorders, allergy and immunology, infectious diseases, general biomedical research, aging, and vision research.
When was this opportunity posted and created?
It was posted and created on February 26, 2009.
What was the closing date for applications?
The original and current closing date listed is January 7, 2012.
Is the opportunity still open?
No. It was archived on February 7, 2012.
Where can someone find the full archived announcement?
NIH provided an additional information link through the NIH Grants Guide for accessing the full archived announcement.
Who should be contacted for access or technical linking issues?
The announcement points to contact options through the NIH Office of Extramural Research (OER) webmaster for access or technical linking issues.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Education Health
Next opportunity: NINDS Ischemic Stroke Genetics Consortium (U01)
Previous opportunity: Manufacturing Processes of Medical, Dental, and Biological Technologies (SBIR R43/R44)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 09 114
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 09 114) also looked into and applied for these:
| Funding Opportunity |
|---|
| Medications Development for the Treatment of Pregnant/Postpartum Women with Substance Related Disorders and/or In Utero Substance Exposed Neonates (R01) Apply for PA 09 106 Funding Number: PA 09 106 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Medications Development for the Treatment of Pregnant/Postpartum Women with Substance Related Disorders and/or In Utero Substance Exposed Neonates (R21) Apply for PA 09 107 Funding Number: PA 09 107 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| The Integrative Cancer Biology Program (ICBP) Centers for Cancer Systems Biology (CCSB) (U54) Apply for RFA CA 09 011 Funding Number: RFA CA 09 011 Agency: National Institutes of Health Category: Education Health Funding Amount: $2,000,000 |
| Clinical Research Curriculum Award (K30) Apply for RFA RR 09 006 Funding Number: RFA RR 09 006 Agency: National Institutes of Health Category: Education Health Funding Amount: $275,000 |
| Research on Clinical Decision Making in People with or at Risk for Life Threatening Illness (R01) Apply for PA 09 122 Funding Number: PA 09 122 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Biobehavioral Methods to Improve Outcomes Research (R21) Apply for PA 09 126 Funding Number: PA 09 126 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Exploratory Grants for Behavioral Research in Cancer Control (R21) Apply for PA 09 130 Funding Number: PA 09 130 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Interventions to Improve Palliative Care at the End of Life (R01) Apply for RFA NR 09 004 Funding Number: RFA NR 09 004 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Incorporating Cost Effectiveness Analysis Into Factors Affecting Quality of Life Health Related Research (R01) Apply for RFA NR 09 005 Funding Number: RFA NR 09 005 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Research on Clinical Decision Making in People with or at Risk for Life Threatening Illness (R21) Apply for PA 09 121 Funding Number: PA 09 121 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Biomedical Research on the International Space Station (BioMed ISS) (UH2/UH3) Apply for PAR 09 120 Funding Number: PAR 09 120 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Building System Capacity for Implementing Evidence Based Practices in Substance Abuse Treatment and Prevention (R34) Apply for PA 09 105 Funding Number: PA 09 105 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Cancer Surveillance Using Health Claims based Data System (R03) Apply for PA 09 143 Funding Number: PA 09 143 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Cancer Surveillance Using Health Claims based Data System (R21) Apply for PA 09 144 Funding Number: PA 09 144 Agency: National Institutes of Health Category: Education Health Funding Amount: $275,000 |
| Cancer Surveillance Using Health Claims based Data System (R01) Apply for PA 09 145 Funding Number: PA 09 145 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Pilot and Feasibility Studies in Preparation for Drug Abuse Prevention Trials (R34) Apply for PA 09 146 Funding Number: PA 09 146 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Economic Studies of Health Insurance Coverage on Drug Abuse Treatment Availability, Access, Costs, and Quality (R01) Apply for RFA DA 10 004 Funding Number: RFA DA 10 004 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Studies of Energy Balance and Cancer in Humans (R01) Apply for PA 09 148 Funding Number: PA 09 148 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Studies of Energy Balance and Cancer in Humans (R21) Apply for PA 09 149 Funding Number: PA 09 149 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Etiology, Prevention, and Treatment of Hepatocellular Carcinoma (P01) Apply for PAR 09 147 Funding Number: PAR 09 147 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 09 114", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.